{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-037122","form_type":"8-K","ticker":null,"cik":"0001603207","company_name":"Notable Labs, Ltd.","filed_at":"2024-09-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.728753+00:00","generated_at":"2026-05-31T03:37:55.508339+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Notable Labs restructures: pauses Phase 2 Volasertib study, cuts 65% of workforce","bullets":["Board approved streamlined operating plan to explore strategic alternatives for maximizing shareholder value.","Phase 2 study of Volasertib in relapsed/refractory AML paused immediately.","Workforce and outside consultants reduced by ~65%; expected completion by September 24, 2024.","Anticipates ~$0.1 million in charges for termination benefits, recognized in Q3 and Q4 2024.","Kaile A. Zagger appointed as Chief Restructuring Officer and Interim CEO."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-037122","json":"https://secwatch.observer/filing/0001493152-24-037122.json","markdown":"https://secwatch.observer/filing/0001493152-24-037122.md","text":"https://secwatch.observer/filing/0001493152-24-037122.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224037122/0001493152-24-037122-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224037122/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T03:37:55.508339+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1b143efa74ba0b2d65c3b41a9d8e1cf9d034cf73","claim":"Notable Labs, Ltd. announced a restructuring with charges of approximately $0.1 million (approximately 65%).","evidence_excerpt":"the Board of Directors also approved: (i) immediately pausing the implementation of the planned Phase 2 study of Volasertib in relapsed/refractory AML (r/r AML), and (ii) a reduction in the Company’s employee workforce and outside consultants by approximately 65%, which the Company expects to substantially complete by September 24, 2024. The Company anticipates recognizing approximately $0.1 million in total charges in connection with the reduction in force","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224037122/0001493152-24-037122-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $0.1 million"},{"label":"Headcount","value":"approximately 65%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}